Camp4 Therapeutics has secured up to $100 million in private financing, initiated GLP toxicology studies for its SYNGAP1 program...

Rezolute set December 2025 as the topline Phase 3 results date for congenital hyperinsulinism and secured FDA alignment that...

Zymeworks reported a catalyst-heavy third quarter: early phase 1 data for its FRα-targeting ADC ZW191 showed encouraging objective response...

Pacira BioSciences reported third-quarter 2025 revenue of $179.5 million, up 6% year over year, with Exparel delivering $139.9 million...

UroGen Pharma reported third-quarter 2025 results, alongside early launch metrics for Zusduri, the first FDA-approved therapy for adults with...

Collegium Pharmaceutical posted a record quarter and raised its outlook. For Q3 2025, the company reported $209.4 million in...

Cognition Therapeutics secured $30 million in a registered direct offering. It reached alignment with the FDA on a potential...

MBX Biosciences reported positive topline data from its phase 2 AVAIL trial of once-weekly canvuparatide in chronic hypoparathyroidism, completed...

Iovance Biotherapeutics posted third-quarter 2025 product revenue of about $68 million, up 13% sequentially, with U.S. sales of its...

Replimune’s BLA resubmission for RP1 in advanced melanoma has been accepted by the FDA, with an April 10, 2026,...